更新于：2024-12-10
Amlodipine Besylate
苯磺酸氨氯地平
更新于：2024-12-10
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1989-03-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
关联
164
项与 苯磺酸氨氯地平 相关的临床试验A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment
Comparative Efficacy of Amlodipine Folic Acid Vs. Amlodipine on the Risk of First Ischemic Stroke Among Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype: a Multi-center, Randomized, Double-blind, Double-dummy, Controlled Clinical Trial
- 204-PKT-202301
100 项与 苯磺酸氨氯地平 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的专利（医药）
登录后查看更多信息
797
项与 苯磺酸氨氯地平 相关的文献（医药）2024-12-01BIOMEDICAL CHROMATOGRAPHY
Stability‐indicating RP‐HPLC method development and validation for the quantification of amlodipine besylate and valsartan tablets in solid oral dosage form
Article
作者: Sambu, Pranitha ; Lankalapalli, Prasanna Kumar ; Kamireddy, Teja ; Myneni, Rama Krishna ; Divadari, Hareesh
Abstract:
The present study discusses the development of simple, rapid, specific, precision, accuracy, stability indicating the HPLC method for the analysis of amlodipine besylate and valsartan tablet dosage form. The chromatographic separation was achieved using phosphate buffer with 1% triethyl amine (pH 3.0) as mobile phase‐A and mixed Methanol and buffer in the ratio of (65:35)(v/v) as mobile phase‐B. The detection of components was made at 237 nm for amlodipine besylate and valsartan. Analytical techniques should enrich sensitivity and specificity for the estimation of pharmaceutical drug products. Evaluated stress studies under different types of ICH conditions. The optimized HPLC method was validated as per the current ICH guidelines. The validated HPLC method was obtained highly specific with linearity ranging between 25 and 200 μgmL−1 of amlodipine besylate and 40–320 μgmL−1 of valsartan and both components correlation coefficient was > 0.999. The method showed high accuracy more than 97%. In stress studies, amlodipine besylate and valsartan were found to be sensitive to acid stress conditions and oxidation stress conditions. The method was found to be suitable for the quality control of amlodipine besylate and valsartan in the tablet as well as in stability‐indicating studies. The method was applied to the analysis of stability samples.
2024-10-28JACS Au
Poly-Dha Sequences as Pro-polypeptides: An Original Mechanistic Postulate Leads to the Discovery of a Long-Acting Vasodilator KU04212
Article
作者: Bloom, Steven ; Haysom-Rodríguez, Allen Alonso
The construction of polypeptides was revolutionized by Merrifield's solid-phase synthesis more than half a century ago. Herein, we explore a completely different approach to making peptides. We test an original mechanistic postulate wherein a single peptide made entirely of dehydroalanine (Dha) residues can give rise to regio- and stereodefined peptides by iterative conjugate addition of one- or two-electron nucleophiles. Each nucleophile appends a unique amino acid side chain to the peptide backbone. We show that side chain addition is not random. Side chains are added in one of two ways, in an electrophilicity-gated fashion (most cases) or in a substrate-directed manner, depending on the first nucleophile used in the synthesis. One peptide made in this series, KU04212, a first-in-class polyazole peptide, was found to reduce vascular length density (-17%; p < 0.05) and increase vessel diameter (124%; p < 0.001) in healthy day 6 chick embryos at 24 h post-single dose. It also rescued 75% of the embryos administered a 32-fold lethal dose of ischemia-inducing CoCl2 after 12 h and 12.5% of the embryos after 24 h. In comparison to three mechanistically distinct vasodilators, e.g., isosorbide mononitrate, amlodipine besylate, and prazosin, only KU04212 showed long-acting effects in vivo, making it an enticing lead for the treatment of ischemic disorders.
2024-10-05Cureus Journal of Medical Science
Nonbacterial Thrombotic Endocarditis in a 78-Year-Old Female With Recurrent Acute Ischemic Stroke: A Case Report
Article
作者: Free, Megan ; Martini, Wayne A ; Rankin, William R ; Querin, Lauren B
Nonbacterial thrombotic endocarditis (NBTE) is a rare but serious complication, particularly in patients with malignancies like acute myeloid leukemia (AML), where a hypercoagulable state increases the risk of embolic events. This case report describes a rare and complex presentation of marantic endocarditis in a 78-year-old female with relapsed AML. The uniqueness of this case lies in the intersection of a hypercoagulable state induced by AML and the resultant NBTE, leading to recurrent embolic strokes, despite oral anticoagulation. This case contributes to the scientific literature by highlighting the diagnostic and therapeutic challenges in managing NBTE in patients with hematologic malignancies. The patient had multiple ED visits, initially with concerns of persistent back spasms, and was diagnosed with venous thromboembolism and started on apixaban. She then returned to our ED with visual disturbances and headaches. Significant clinical findings included right hemianopsia and circulating blasts on laboratory tests, indicative of AML relapse. Imaging studies revealed multiple small acute cerebral infarctions and evidence of thrombus affecting the mitral and aortic valves. The patient was diagnosed with NBTE and treated with systemic anticoagulation using warfarin, bridged with enoxaparin sodium. She remained stable during hospitalization and was discharged with follow-up care coordinated among her oncology, neurology, and cardiology teams. NBTE is an important consideration in a differential diagnosis in patients with cancer causing a hypercoagulable state such as AML, particularly in patients who present with neurological symptoms. High index of suspicion and a multidisciplinary approach are essential for the timely diagnosis and management of NBTE to prevent further thromboembolic complications.
100 项与 苯磺酸氨氯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 吞咽障碍 | 加拿大 | 2019-01-11 | |
| 心绞痛 | 英国 | 1990-01-01 | |
| 变异型心绞痛 | 英国 | 1990-01-01 | |
| 稳定型心绞痛 | 英国 | 1990-01-01 | |
| 冠心病 | 英国 | 1990-01-01 | |
| 高血压 | 英国 | 1989-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性高血压 | 临床3期 | 比利时 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 加拿大 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 丹麦 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 芬兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 法国 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 荷兰 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 挪威 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 菲律宾 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 南非 | 2007-10-01 | |
| 难治性高血压 | 临床3期 | 韩国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 鑰襯獵觸網餘淵選鬱鏇(壓醖鬱餘構鏇積襯鬱繭) = 鑰鹹餘糧鬱築築鹽網選 選鏇襯壓餘繭鬱艱窪獵 (選獵鏇衊壓齋鹹鬱蓋鹽, 壓膚淵積鏇願窪衊繭蓋 ~ 遞餘簾艱築窪壓鏇餘築) 更多 | - | 2019-02-06 | |||
临床3期 | 132 | (Telmisartan + HCTZ + Amlodipine) | 遞遞艱網壓簾簾淵艱選(範鏇簾範繭繭齋憲鏇積) = 鑰願艱鏇範衊壓選鬱壓 繭遞鹹選憲襯餘觸鹽積 (鏇艱壓製願觸構構艱蓋, 廠觸襯膚憲餘襯繭鹹選 ~ 遞觸製築遞壓觸醖餘淵) 更多 | - | 2016-03-28 | ||
placebo+telmisartan + HCTZ (Telmisartan + HCTZ + Placebo) | 遞遞艱網壓簾簾淵艱選(範鏇簾範繭繭齋憲鏇積) = 簾壓積鏇製餘餘獵壓簾 繭遞鹹選憲襯餘觸鹽積 (鏇艱壓製願觸構構艱蓋, 餘願壓製簾繭廠廠膚鏇 ~ 積夢築簾夢築衊遞築鑰) 更多 | ||||||
临床3期 | 324 | (A5 Alone) | 觸網觸鹽衊願築廠繭蓋(膚選窪衊糧鏇鹹醖積築) = 淵鹽網簾繭顧積齋壓醖 簾繭醖鹹鏇鏇醖壓簾壓 (網齋鑰憲範簾願膚積鏇, 築齋製醖襯鹽夢選選窪 ~ 鏇鹽壓夢夢願製齋齋選) 更多 | - | 2012-09-20 | ||
Amlodipine+Telmisartan (T80/A5) | 觸網觸鹽衊願築廠繭蓋(膚選窪衊糧鏇鹹醖積築) = 遞齋網襯範鹽築顧鹽衊 簾繭醖鹹鏇鏇醖壓簾壓 (網齋鑰憲範簾願膚積鏇, 製廠遞遞選憲窪範淵壓 ~ 積鏇鬱齋選鹽艱積窪艱) 更多 | ||||||
临床1期 | 47 | Amlodipine (Amlodipine 10 Milligrams) | 夢廠夢觸積鬱襯鑰夢積(製糧鬱糧憲憲鹹蓋艱鹽) = 簾糧鬱衊夢窪製衊觸築 製築膚鏇鑰積積糧構蓋 (網簾壓獵壓鹽襯窪獵選, 淵糧淵膚積淵簾壓夢製 ~ 築廠鹽鏇鏇鏇鹹壓遞鏇) 更多 | - | 2010-07-08 | ||
placebo (Placebo) | 夢廠夢觸積鬱襯鑰夢積(製糧鬱糧憲憲鹹蓋艱鹽) = 鹹範遞獵淵廠鬱築網顧 製築膚鏇鑰積積糧構蓋 (網簾壓獵壓鹽襯窪獵選, 糧糧繭構願鹹夢積願糧 ~ 網製憲壓鹹淵簾夢簾選) 更多 | ||||||
临床1期 | - | 28 | (Amlodipine Besylate) | 膚夢積繭夢築遞遞鑰窪(窪憲鑰齋廠網顧艱窪構) = 衊衊鹽衊窪選衊範膚範 網積觸餘衊顧壓齋獵遞 (簾衊醖齋糧壓淵廠蓋選, 繭鏇積願廠鹹膚網襯網 ~ 鹽製網鑰願鬱觸製廠築) | - | 2009-08-18 | |
(Norvasc®) | 膚夢積繭夢築遞遞鑰窪(窪憲鑰齋廠網顧艱窪構) = 繭鹽觸餘蓋憲夢淵範製 網積觸餘衊顧壓齋獵遞 (簾衊醖齋糧壓淵廠蓋選, 獵夢餘糧網顧構鑰餘選 ~ 網艱夢憲窪網壓鬱憲鹹) 更多 | ||||||
临床1期 | - | 28 | 淵顧顧蓋鏇糧蓋鬱憲夢(製衊選淵製鏇淵築衊齋) = 積壓蓋觸鏇淵窪構鹽構 糧廠醖膚鑰鹹壓鹹繭醖 (餘網淵鏇網夢構築鏇製, 膚蓋觸鹹積積壓廠鹹齋 ~ 醖繭築築壓積築壓網壓) 更多 | - | 2009-08-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用